In this Healthed lecture, Dr Ted Wu explores the impact of cardiovascular outcomes trials in patients with type 2 diabetes, which have led to significant advances in cardioprotective therapies. As a result of these trials, medications such as SGLT2 inhibitors and GLP1 receptor agonists are now recommended as first-line treatments for individuals with, or at risk of, cardiovascular disease. Dr Wu addresses the pressing question of what comes next in this evolving field. This lecture focuses on the opportunities and challenges that future research is likely to face as it continues to investigate cardiovascular outcomes in patients living with type 2 diabetes.

See omnystudio.com/listener for privacy information.